Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Osaic Holdings Inc.

Osaic Holdings Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 55.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,068 shares of the biopharmaceutical company’s stock after purchasing an additional 6,073 shares during the period. Osaic Holdings Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,607,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Activest Wealth Management boosted its position in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the period. Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $31,000. Traub Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $38,000. Finally, Berbice Capital Management LLC grew its stake in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 60 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $767.96 on Friday. The stock has a market capitalization of $80.71 billion, a price-to-earnings ratio of 18.39, a P/E/G ratio of 2.21 and a beta of 0.37. The firm’s 50-day moving average price is $682.40 and its two-hundred day moving average price is $600.42. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $790.98.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the previous year, the business posted $12.46 earnings per share. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Analyst Ratings Changes

Several brokerages recently weighed in on REGN. Truist Financial assumed coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $798.00 target price for the company. Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Jefferies Financial Group upped their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $779.45.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.